A multicenter trial of alogliptin for the safety and efficacy on glycemic control in Japanese type 2 diabetic patients undergoing hemodialysis
Not Applicable
Recruiting
- Conditions
- Type 2 diabetic patients undergoing hemodialysis
- Registration Number
- JPRN-UMIN000006082
- Lead Sponsor
- Tokyo Women's Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) Type 1 diabetic patients 2) Patients with insulin dose equal to or greater than 15 unit per day 3) Patients with liver disease 4) Patients with cancer disease 5) Patients with inflammatory disease 6) patients considered as inadequate by the principal investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in QOL, plasma glucose, HbA1c and glycated alubmin levels(0, 4, 8, 12, 16, 20 and 24 weeks after starting of treatment)
- Secondary Outcome Measures
Name Time Method C-peptide and glucagon levels(0 and 24 weeks after starting of treatment)